Molecular Inflammation Board at the Center for Personalized Medicine

NCT07132333 · tracked via the Priya Life Science Germany tracker

Sponsor

University Hospital Tuebingen

Phase

Observational

Started

2022-11-16

Last updated

2025-08-20

Condition(s) studied

Psoriasis (PsO)Psoriasis ArthritisInflammatory Bowel Disease (Crohn's Disease and Ulcerative Colitis)Spondylarthropathies

Investigational drug(s) / intervention(s)

Biologic Agent

Biologic Agent: Intervention with biologic agents

Study summary

Molecular Inflammation Board at the Center for Personalized Medicine

Eligibility

Sex

ALL

Min age

18 Years

Max age

—

Healthy volunteers

Inclusion Criteria: * Chronic inflammatory disorder (PsO, PsA, SpA, IBD) * Given informed consent * 18 years of age Exclusion Criteria: * No capacity to consent

Primary outcome measure(s)

Therapy persistence — Through study completion, an average of 1 year
Duration of intervention with biological agent

Trial sites (1)

Facility	City	Region	Status
University Hospital of Tübingen - Center for Personalized Medicine	Tübingen	Germany	Recruiting

More University Hospital Tuebingen trials in Germany

A Strong Start in Life - ELAS 2.0: A Digital Learning Program to Promote a Healthy Pregnancy and Early Child Protection Starting soon

Identification of Risk Factors, Exposomics and Genetic Susceptibility of Melanoma in Children, Adolescents and Young Adults Recruiting

PREG - Offspring: Investigation of Children From Mothers With and Without Gestational Diabetes Recruiting

The preSPG4 Study - Studying the Prodromal and Early Phase of SPG4 Recruiting

Feasibility of Online MR-guided Radiotherapy on a 1.5T MR-Linac Recruiting

Other trials for the same condition

Exploratory Clinical Study on Fasting in Psoriasis and Psoriatic Arthritis (RiseFast) Active, not recruiting

Long-term Safety and Efficacy of ESK-001 in Moderate to Severe Plaque Psoriasis Active, not recruiting

Official registry record

This page summarises publicly available registry data for informational purposes — not medical advice. Eligibility is determined by each study team; patients should discuss participation with their clinician.

View NCT07132333 on ClinicalTrials.gov ↗ ← All trials in Germany